Combination Therapy With Immunomodulators Improves the Pharmacokinetics of Infliximab But Not Vedolizumab or Ustekinumab
Andrés Yarur, Dermot McGovern, María T. Abreu, Adam S. Cheifetz, Konstantinos Papamichail, Parakkal Deepak, Alexandra Bruss, Poonam Beniwal‐Patel, Marla Dubinsky, Stephan Targan, Gil Melmed
Topics & Concepts
MedicineVedolizumabInfliximabThiopurine methyltransferaseUstekinumabMethotrexateGastroenterologyUlcerative colitisInternal medicineInflammatory bowel diseaseCrohn's diseasePharmacologyDiseaseInflammatory Bowel DiseaseLiver Diseases and ImmunityBiosimilars and Bioanalytical Methods